Option chain shows key data for Vizsla Silver's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Vizsla Silver.

Vizsla Silver (AMEX:VZLA) Stock, Option Chain

Vizsla Silver

Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.

Movers

News

Pre-Market Outlook

Markets

Trading Ideas

HYLN

ITOS

MRNO

MSTR

NVMI

SLDB

UPST

VZLA

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

Vizsla Silver Corp

Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) just disclosed its Q4 earnings on Friday, February 7, 2025 at 07:30 AM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Fortive beat estimated earnings by 4.0%, reporting an EPS of $1.17 versus an estimate of $1.12.
Revenue was up $36.00 million from the same period last year.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat on EPS by $0.04 which was followed by a 1.0% drop in the share price the next day.
Here's a look at Fortive's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.93</td>
<td>0.92</td>
<td>0.79</td>
<td>0.94</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.97</td>
<td>0.93</td>
<td>0.83</td>
<td>0.98</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.55B</td>
<td>1.57B</td>
<td>1.53B</td>
<td>1.56B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.53B</td>
<td>1.55B</td>
<td>1.52B</td>
<td>1.58B</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Fortive management provided guidance for Q1 2025, expecting earnings between $0.83 and $0.86 per share.
To track all earnings releases for Fortive <a href="https://www.benzinga.com/quote/FTV/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Fortive Q4 Earnings Assessment

On Friday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with hemophilia A with and without inhibitors.
The <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915260" rel="noreferrer noopener">trial</a> initially assessed once-weekly prophylaxis treatment (regular treatment to prevent prolonged and spontaneous bleeding) with investigational Mim8 before giving participants the option to change to once-monthly dosing after 26 weeks.
In part one of the FRONTIER3 study, participants received once-weekly doses of Mim8 for 26 weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43491991/novo-nordisk-records-more-than-double-wegovy-sales-in-q4-seeks-regulatory-approval-for-hybrid-weight-loss-drug-in-2026" rel="noreferrer noopener">Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026</a>
In part two, participants could continue with once-weekly dosing or move to once-monthly dosing for the remaining 26 weeks.
<ul>
<li>The interim analysis reports results after part one of the study, with some preliminary data shared from part two, which continued following this analysis.</li>
<li>For part one of the study in children on once-weekly prophylaxis, the estimated mean (average) annualized bleeding rate (ABR) for treated bleeds was 0.53.</li>
</ul>
The median ABR was zero; 74.3% of participants had zero treated bleeds.
All children with hemophilia A with inhibitors (n=14) reported zero treated bleeds. After completing the initial 26 weeks of the study, 45% of participants moved to once-monthly Mim8, and the rest (55%) remained on the once-weekly dose.
The data showed that Mim8 was well-tolerated and efficacious.
Novo Nordisk expects Mim8 regulatory submission during 2025. Data from the ongoing phase 3 FRONTIER program will be disclosed at upcoming congresses and in publications in 2025 and 2026.
In May 2024, Novo Nordisk released headline results from the FRONTIER 2 Phase 3a trial of once-weekly and once-monthly subcutaneous Mim8 versus no prophylaxis and versus prior coagulation factor prophylaxis treatment in hemophilia A patients 12 years or older <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38797768/novo-nordisks-hemophilia-candidate-can-prevent-bleeding-episodes-effectively-regardless-of-dosing" rel="noreferrer noopener">with or without inhibitors</a>.
The trial achieved its co-primary endpoints by demonstrating a statistically significant and superior reduction of treated bleeding episodes with both once-weekly and once-monthly Mim8 versus no prophylaxis treatment and prior coagulation factor prophylaxis treatment.
In June 2024,&nbsp;Novo Nordisk acquired the Hemophilia A program and rights to 2seventy Bio Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies of immune&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39532373/novo-nordisk-buys-2seventys-hemophilia-a-program-divestiture-supports-exclusive-focus-on-abecma" rel="noreferrer noopener">cells for autoimmune disease</a>.
Price Action: NVO stock is down 2.33% at $89.20 during the premarket session on last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43542288/block-poised-for-growth-in-2025-analyst-predicts-outperformance-and-possible-sp-500-spot" target="_blank" rel="noreferrer noopener">Block In The S&amp;P500? BofA Analyst Says Company Meets All Criteria</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

General

TSVT

Novo Nordisk Eyes 2025 Regulatory Filing For Hemophilia Candidate After Encouraging Pediatric Study Data

The earnings results for Cboe Global Markets (BATS:<a class="ticker" href="https://www.benzinga.com/stock/CBOE#BATS">CBOE</a>) for Q4 were made public on Friday, February 7, 2025 at 07:30 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Cboe Global Markets missed estimated earnings by -1.0%, reporting an EPS of $2.1 versus an estimate of $2.12.
Revenue was up $25.50 million from the same period last year.
<h3>Past Earnings Performance</h3>
The company beat on EPS by $0.03 in the previous quarter, leading to a 2.0% drop share price change the next day.
Here's a look at Cboe Global Markets's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.19</td>
<td>2.10</td>
<td>2.04</td>
<td>2.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.22</td>
<td>2.15</td>
<td>2.15</td>
<td>2.06</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>530.76M</td>
<td>514.51M</td>
<td>504.80M</td>
<td>511.68M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>532.00M</td>
<td>513.80M</td>
<td>502.10M</td>
<td>499.00M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Cboe Global Markets <a href="https://www.benzinga.com/quote/CBOE/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CBOE

Cboe Global Markets Earnings Report: Q4 Overview

Rosenblatt analyst Mike Genovese maintains Extreme Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXTR#NASDAQ">EXTR</a>) with a Buy and maintains $22 price target.

Price Target

Analyst Ratings

EXTR

Rosenblatt Maintains Buy on Extreme Networks, Maintains $22 Price Target

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) with a Outperform and lowers the price target from $108 to $95.

Barrington Research Maintains Outperform on Haemonetics, Lowers Price Target to $95

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and maintains $80 price target.

Reiteration

CORT

HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $80 Price Target

Barrington Research analyst Alexander Paris maintains Perdoceo Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRDO#NASDAQ">PRDO</a>) with a Outperform and maintains $32 price target.

PRDO

Barrington Research Maintains Outperform on Perdoceo Education, Maintains $32 Price Target

Snap Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) CEO, Evan Spiegel, has taken a playful jab at Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) for its history of mimicking Snapchat&#8217;s features in a way that seems to mock the social media giant.
What Happened: Spiegel updated his LinkedIn profile that now read, &#8220;Loving husband, father of four boys, VP Product @ Meta,&#8221; indicates a Fortune <a href="https://fortune.com/2025/02/06/snap-ceo-evan-spiegel-mocks-mark-zuckerberg-meta-copycat-features/">report</a>. This update is widely interpreted as a swipe at Meta&#8217;s penchant for copying Snapchat&#8217;s features.
Despite Mark Zuckerberg&#8216;s&nbsp;$3 billion acquisition offer in&nbsp;2013, Spiegel has staunchly upheld Snap&#8217;s independence. Meta, in turn, has launched features remarkably similar to Snapchat&#8217;s, including Instagram Stories, disappearing direct messages, and face-distorting filters.
Spiegel, in a 2018 conference, shared mixed feelings about Meta&#8217;s imitation, stating, &#8220;It was the best feeling to design something that is so simple and so elegant that the only thing competitors can do is copy it exactly.&#8221; 
He also humorously suggested that Meta should replicate Snapchat&#8217;s data protection practices.
SEE ALSO: <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43527542/meta-stock-soars-but-zuckerbergs-cashing-in-should-investors-worry">Meta Stock Soars, But Zuckerberg&#8217;s Cashing In &#8211; Should Investors Worry?</a>
Why It Matters: A CNBC report in Jan indicated that Meta is providing incentives to creators to advertise Instagram on competing short-form video platforms like TikTok, Snapchat, and YouTube to gain a larger share. This move highlights the intense competition in the social media space, as platforms battle for the attention of millions of users while TikTok&#8217;s future remains uncertain.
Meanwhile, Snap has been grappling with its own challenges. Despite reporting a fourth-quarter <a href="https://www.benzinga.com/25/02/43504595/snap-falls-despite-q4-beat-as-analysts-remain-cautious-on-ad-growth-and-higher-expenses">earnings beat</a>, Snap&#8217;s shares fell as analysts expressed concerns over ad growth and higher expenses.
Last week, Meta announced its fourth-quarter results, surpassing expectations for both revenue and earnings, while reaffirming its commitment to significant AI-related investments.
Snap has a much smaller user base when compared to Meta, but it has posted impressive growth for the fourth quarter. Meta&#8217;s Family Daily Active People (DAP)&nbsp;grew 5.5% year-on-year to 3.35 billion, while Snap&#8217;s Daily Active Users increased 9% year-over-year to 453 million. 
<ul>
<li>READ ALSO: <a href="https://www.benzinga.com/markets/25/02/43552448/pinterests-gen-z-boom-engagement-hits-62-all-time-high-as-advertiser-clicks-surge-90heres-whats-driving-the-growth-for-this-meta-rival">Pinterest&#8217;s Gen Z Boom: Engagement Hits All-Time High As Advertiser Clicks Surge 90%—What&#8217;s Working For The Meta Rival</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Tech

SNAP

Evan Spiegel Takes A Shot At Mark Zuckerberg Over Meta Copying Snapchat's Features On Instagram And Facebook

Guidance

Flowers Foods Sees FY25 Revenue Of $5.403B -$5.487B Vs. $5.22B Est; Adj EPS Of $1.11 - $1.24 Vs. $1.3 Est.

For the&nbsp;first quarter&nbsp;of 2025, Fortive anticipates revenue of&nbsp;$1.48 billion&nbsp;to&nbsp;$1.51 billion, diluted net earnings per share of&nbsp;$0.39&nbsp;to&nbsp;$0.42, and adjusted diluted net earnings per share of&nbsp;$0.83&nbsp;to&nbsp;$0.86.

Fortive Q1 Guidance: Expects Revenue Of ~$1.48B-$1.51B Vs. $1.565B Est.; Sees Adjusted EPS Between $$0.83-$0.86 Vs. $0.91 Est.

Barrington Research analyst Patrick Sholl maintains Lions Gate Enter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGF#NYSE">LGF</a>) with a Outperform and maintains $12 price target.

Lions Gate Entertainment Corporation Class A Voting Shares

LGF/A

Barrington Research Maintains Outperform on Lions Gate Enter, Maintains $12 Price Target

The earnings results for Plains GP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAGP#NASDAQ">PAGP</a>) for Q4 were made public on Friday, February 7, 2025 at 07:03 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Plains GP Holdings missed estimated earnings by -111.00000000000001%, reporting an EPS of $-0.05 versus an estimate of $0.46.
Revenue was down $296.00 million from the same period last year.
<h3>Previous Earnings Records</h3>
In the previous quarter, the company missed on EPS by $0.12, resulting in a 3.0% drop change in the share price the following day.
Here's a look at Plains GP Holdings's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.29</td>
<td>0.29</td>
<td>0.28</td>
<td>0.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.17</td>
<td>0.20</td>
<td>0.21</td>
<td>0.27</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>13.11B</td>
<td>12.35B</td>
<td>12.79B</td>
<td>11.91B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>12.74B</td>
<td>12.93B</td>
<td>11.99B</td>
<td>12.70B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Plains GP Holdings <a href="https://www.benzinga.com/quote/PAGP/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PAGP

Plains GP Holdings Earnings Review: Q4 Summary

The earnings results for Banco Santander Chile (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSAC#NYSE">BSAC</a>) for Q4 were made public on Friday, February 7, 2025 at 07:00 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Banco Santander Chile missed estimated earnings by -16.0%, reporting an EPS of $0.59 versus an estimate of $0.7.
Revenue was up $169.57 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
The company missed on EPS by $0.09 in the previous quarter, leading to a 1.0% drop share price change the next day.
Here's a look at Banco Santander Chile's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.67</td>
<td>0.49</td>
<td>0.36</td>
<td>0.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.58</td>
<td>0.49</td>
<td>0.26</td>
<td>0.43</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>723.81M</td>
<td>685.66M</td>
<td>614.81M</td>
<td>627.37M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>593.73M</td>
<td>534.55M</td>
<td>500.85M</td>
<td>414.03M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Banco Santander Chile <a href="https://www.benzinga.com/quote/BSAC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSAC

Banco Santander Chile Q4 Earnings Report: What Investors Need to Know

For the full year 2025, Fortive anticipates revenue of approximately $6.23 billion to $6.35 billion, diluted net earnings per share of $2.38 to $2.50, and adjusted diluted net earnings per share of $4.00 to $4.12. The
For the full year 2025, Fortive anticipates revenue of approximately $6.23 billion to $6.35 billion, diluted net earnings per share of $2.38 to $2.50, and adjusted diluted net earnings per share of $4.00 to $4.12. The foregoing guidance for the full year 2025 does not give effect to the pending separation of the Precision Technologies segment.

Fortive Provides 2025 Guidance: Expects Revenue Of $6.23B-$6.35B Vs. $6.488B Est.; Sees Adjusted EPS Between $4-$4.12 Vs. $3.85 Est.

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) with a Buy and maintains $1.5 price target.

XFOR

HC Wainwright & Co. Reiterates Buy on X4 Pharmaceuticals, Maintains $1.5 Price Target

Barrington Research analyst Gary Prestopino maintains Cantaloupe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTLP#NASDAQ">CTLP</a>) with a Outperform and maintains $12 price target.

CTLP

Barrington Research Maintains Outperform on Cantaloupe, Maintains $12 Price Target

Needham analyst Tom Nikic reiterates Skechers USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) from Hold to Hold.

Needham Reiterates Hold on Skechers USAto Hold

iQIYI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) saw its shares rise in premarket trading on Friday following the release of its viewership data and content trends for the Chinese New Year holiday period, spanning <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">from January 28 to February 4.</a>
The company said that the platform&#8217;s performance was driven by the popularity of classic IPs, including blockbuster films, which fueled a surge in online viewership and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43555947/iqiyi-sees-surge-in-viewership-during-chinese-new-year-users-favor-classic-ips-long-and-short-cont" rel="noreferrer noopener">overall platform engagement.</a>
In addition, increasing content diversity, such as long-form videos and mini-dramas, captivated audiences, highlighting evolving content preferences.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, IQ stock has lost over 32% in the past year.
Variety shows played a significant role, with iQIYI&#8217;s variety show channel seeing the highest viewing time during the holiday.
The 2025 Spring Festival Gala, produced by China Media Group, maintained its top position in the variety show rankings.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/25/02/43543297/xrp-down-26-in-7-days-whats-going-on" rel="noreferrer noopener">XRP Down 26% In 7 Days: What&#8217;s Going On?</a>
iQIYI International experienced a 135% year-on-year increase in average viewing time per user for the global livestream. The platform&#8217;s original variety shows also gained strong traction, such as the travel-themed &#8220;The Blooming Journey&#8221; and comedy hits like &#8220;The King of Stand-Up Comedy&#8221; and &#8220;Super Sketch Show.&#8221;
Premium dramas also resonated with viewers, with series like The White Olive Tree, Moonlight Mystique, and Unbreakable 2 dominating content rankings. Notably, Unbreakable 2 sparked renewed interest in its predecessor, leading to a boost in Season 1&#8217;s viewership.
Mini-dramas also gained popularity, with over 70% of their audience aged 35 and below, the company said.
Sequel films, such as Ne Zha 2 and Legends of the Condor Heroes: The Gallants, drove strong viewership for earlier related films and content. iQIYI also saw a boost in animation and kids&#8217; content, including How Dare You!?, PAW Patrol, and Peppa Pig.
Engagement was enhanced through interactive features, including a 118% year-on-year increase in bullet comments and AI-powered chats with fictional characters.
The launch of VR immersive theater experiences also saw significant growth, with a 206% increase in visitor numbers, contributing to the platform&#8217;s successful holiday period.
Price Action: IQ shares are trading higher by 2.58% to $2.39 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43545590/amazoncom-q4-earnings-highlights-revenue-beat-eps-beat-most-successful-holiday-shopping-season-in-company-history" target="_blank" rel="noreferrer noopener">Amazon.com Q4 Earnings: Jassy Highlights &#8216;Successful&#8217; Holiday Season, Q1 Guidance Disappoints Investors</a></li>
</ul>
Image via Shutterstock.

Equities

Why Is iQIYI Stock Gaining Today?

Barrington Research analyst Patrick Sholl maintains QuinStreet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNST#NASDAQ">QNST</a>) with a Outperform and maintains $29 price target.

QNST

Barrington Research Maintains Outperform on QuinStreet, Maintains $29 Price Target

HC Wainwright &amp; Co. analyst Ed Arce reiterates Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) with a Buy and maintains $13 price target.

GNFT

HC Wainwright & Co. Reiterates Buy on Genfit, Maintains $13 Price Target

Small Cap

Press Releases

VIZSLA SILVER RECEIVES FINAL APPROVAL TO GRADUATE TO THE TORONTO STOCK EXCHANGE

VIZSLA COPPER INTERSECTS MINERALIZED BRECCIA IN EXPLORATION DRILLING NEAR THE THREE FIRS TARGET, WOODJAM PROJECT

VIZSLA SILVER COMMENCES TEST MINING AND BULK SAMPLE PROGRAM AND PROVIDES EXPLORATION UPDATE AT PANUCO PROJECT

VIZSLA SILVER ANNOUNCES 43% INCREASE IN MEASURED AND INDICATED MINERAL RESOURCES AT PANUCO, INCLUDING 46 MOZ GRADING 640 G/T AGEQ IN FIRST MEASURED RESOURCE ESTIMATE

Comments

Vizsla Silver

Vizsla Silver (VZLA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga